Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 232

The DOI matches its Crossref record.

Antithrombotic treatment with direct‐acting oral anticoagulants in patients with splanchnic vein thrombosis and cirrhosis

Open access
De Gottardi, Andrea, Trebicka, Jonel, Klinger, Christoph, Plessier, Aurélie, Seijo, Susana, Terziroli, Benedetta, Magenta, Lorenzo, Semela, David, Buscarini, Elisabetta, Langlet, Philippe, Görtzen, Jan, Puente, Angela, Müllhaupt, Beat, Navascuès, Carmen, Nery, Filipe, Deltenre, Pierre, Turon, Fanny, Engelmann, Cornelius, Arya, Rupen, Caca, Karel, Peck‐Radosavljevic, Markus, Leebeek, Frank W. G., Valla, Dominique, Garcia‐Pagan, Juan Carlos, the VALDIG Investigators · 2017 · Liver International

Abstract

Background: Direct‐acting oral anticoagulants (DOAC s) are used in patients with splanchnic vein thrombosis (SVT) and cirrhosis, but evidence for safety and efficacy in this setting is limited. Our aim was to identify indications and reasons for starting or switching to DOAC s and to report adverse effects, complications and short‐term outcome. Methods: Data collection including demographic information, laboratory values, treatment and complications through the Vascular Liver Disease Interest Group Consortium. Results: Forty‐five centres (90%) of the consortium completed the initial eCRF. We report here a series of 94 patients from 17 centres. Thirty‐six patients (38%) had cirrhosis. Child‐Pugh score was 6 (range 5‐8), and MELD score 10.2 (range 6‐19). Indications for anticoagulation were splanchnic vein thrombosis (75%), deep vein thrombosis (5%), atrial fibrillation (14%) and others (6%). DOAC s used were rivaroxaban (83%), dabigatran (11%) and apixaban (6%). Patients were followed up for a median duration of 15 months (cirrhotic) and 26.5 months (non‐cirrhotic). Adverse events occurred in 17% of patients and included one case of recurrent portal vein thrombosis and five cases of bleeding. Treatment with DOAC s was stopped in three cases. The major reasons for choosing DOAC s were no need for monitoring or inadequacy of INR to guide anticoagulation in cirrhotic patients. Renal and liver function did not change during treatment. Conclusions: A consistent number of patients with SVT and/or cirrhosis are currently treated with DOAC s, which seem to be effective and safe. These data provide a basis for performing randomized clinical trials of DOAC s vs. low molecular weight heparin or vitamin K antagonists.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/liv.13285

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 232

Metadata

Authors
De Gottardi, A., Trebicka, J., Klinger, C., Plessier, A., Seijo, S., Terziroli, B., Magenta, L., Semela, D., Buscarini, E., Langlet, P., Görtzen, J., Puente, A., Müllhaupt, B., Navascuès, C., Nery, F., Deltenre, P., Turon, F., Engelmann, C., Arya, R., Caca, K., Peck‐Radosavljevic, M., Leebeek, F. W. G., Valla, D., Garcia‐Pagan, J. C., & the VALDIG Investigators
Venue
Liver International
Publisher
Wiley
Published
2016-11-19
Volume
37
Issue
5
Pages
694-699
ISSN
  • 0106-9543 (ISSN-L)
  • 1478-3223
  • 1478-3231
OpenAlex
W2533474819
Cited by
232
References
0
FWCI
18.42
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Antithrombotic treatment with direct‐acting oral anticoagulants in patients with splanchnic vein thrombosis and cirrhosis. https://app.cochat.ai/papers/10.1111/liv.13285
The paper
De Gottardi, A., Trebicka, J., Klinger, C., Plessier, A., Seijo, S., Terziroli, B., Magenta, L., Semela, D., Buscarini, E., Langlet, P., Görtzen, J., Puente, A., Müllhaupt, B., Navascuès, C., Nery, F., Deltenre, P., Turon, F., Engelmann, C., Arya, R., . . . the VALDIG Investigators. (2017). Antithrombotic treatment with direct‐acting oral anticoagulants in patients with splanchnic vein thrombosis and cirrhosis. Liver International. https://doi.org/10.1111/liv.13285

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.